LNTH Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 19.57% compared to Lantheus Holdings's net margin of --. Lantheus Holdings's return on equity of 23.53% beat Perspective Therapeutics's return on equity of --.

Lantheus Holdings has a consensus price target of $130.08, signalling upside risk potential of 59.14%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Perspective Therapeutics has higher upside potential than Lantheus Holdings, analysts believe Perspective Therapeutics is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.233, which suggesting that the stock is 76.662% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Lantheus Holdings's net income of $72.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.22x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.83x versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of 19.57% compared to Lantheus Holdings's net margin of 12.11%. Lantheus Holdings's return on equity of 23.53% beat Electromed's return on equity of 15.91%.

Lantheus Holdings has a consensus price target of $130.08, signalling upside risk potential of 59.14%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.14%. Given that Electromed has higher upside potential than Lantheus Holdings, analysts believe Electromed is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.233, which suggesting that the stock is 76.662% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Electromed quarterly revenues of $16.3M. Lantheus Holdings's net income of $72.9M is higher than Electromed's net income of $2M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.22x while Electromed's PE ratio is 29.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.83x versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Enovis has a net margin of 19.57% compared to Lantheus Holdings's net margin of -10.02%. Lantheus Holdings's return on equity of 23.53% beat Enovis's return on equity of -26.77%.

Lantheus Holdings has a consensus price target of $130.08, signalling upside risk potential of 59.14%. On the other hand Enovis has an analysts' consensus of $59.00 which suggests that it could grow by 78.52%. Given that Enovis has higher upside potential than Lantheus Holdings, analysts believe Enovis is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.233, which suggesting that the stock is 76.662% less volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Enovis quarterly revenues of $558.8M. Lantheus Holdings's net income of $72.9M is higher than Enovis's net income of -$56M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.22x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.83x versus 0.86x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of 19.57% compared to Lantheus Holdings's net margin of -1.73%. Lantheus Holdings's return on equity of 23.53% beat Hologic's return on equity of 11.45%.

Lantheus Holdings has a consensus price target of $130.08, signalling upside risk potential of 59.14%. On the other hand Hologic has an analysts' consensus of $67.96 which suggests that it could grow by 19.75%. Given that Lantheus Holdings has higher upside potential than Hologic, analysts believe Lantheus Holdings is more attractive than Hologic.

Lantheus Holdings has a beta of 0.233, which suggesting that the stock is 76.662% less volatile than S&P 500. In comparison Hologic has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.552%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Hologic quarterly revenues of $1B. Lantheus Holdings's net income of $72.9M is higher than Hologic's net income of -$17.4M. Notably, Lantheus Holdings's price-to-earnings ratio is 23.22x while Hologic's PE ratio is 23.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.83x versus 3.28x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.